Day One BiopharmaceuticalsDAWN 12 Gross Margin % is 88.68% as of Dec. 2025, which is 4% below its 10-year median of 92.55. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Day One Biopharmaceuticals ranks better than 83.06% on this metric.
Day One Biopharmaceuticals (NAS:DAWN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Day One Biopharmaceuticals had a gross margin of 88.68% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Day One Biopharmaceuticals Gross Margin % Related Terms
Day One Biopharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DAWN vs TYRA, DFTX, MLYS: Gross Margin % Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Day One Biopharmaceuticals (DAWN) has a Gross Margin % of 88.68% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Day One Biopharmaceuticals and its competitors. This is near median its historical median of 92.55. Over the past decade, Day One Biopharmaceuticals' Gross Margin % has ranged from 89.12 to 95.98. According to the industry distribution chart, Day One Biopharmaceuticals ranks #125 out of 738 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Day One Biopharmaceuticals' Gross Margin % too high?
Day One Biopharmaceuticals' current Gross Margin % of 88.68% is near median its 10-year median of 92.55. Over the past 10 years, this metric has ranged from a low of 89.12 to a high of 95.98. The Biotechnology industry median Gross Margin % is 60.94. Day One Biopharmaceuticals' value of 88.68% is 45.5% above this industry median. Based on the distribution chart, Day One Biopharmaceuticals ranks #125 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Gross Margin % compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #125 out of 738 companies for Gross Margin %. This places Day One Biopharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Day One Biopharmaceuticals' value of 88.68% is 45.5% above this benchmark. Historically, Day One Biopharmaceuticals' own Gross Margin % has ranged from 89.12 to 95.98 over the past decade. While the company's 10-year median is 92.55 vs. the industry median of 60.94, Day One Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current Gross Margin % of 88.68% is 45.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Day One Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current Gross Margin % is 88.68%, which is near median its own 10-year median of 92.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Gross Margin % of 88.68%. The current Gross Margin % is 88.68%, which is near median its 10-year median of 92.55 and 45.5% above the Biotechnology industry median of 60.94. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Gross Margin % is 88.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
